{"id":"anthracycline-cyclophosphamide-docetaxel-capecitabine","safety":{"commonSideEffects":[{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Mucositis"},{"rate":null,"effect":"Cardiotoxicity (anthracycline-related)"},{"rate":null,"effect":"Peripheral neuropathy (docetaxel-related)"},{"rate":null,"effect":"Hand-foot syndrome (capecitabine-related)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Anthracyclines intercalate into DNA and generate reactive oxygen species to kill rapidly dividing cells. Cyclophosphamide is an alkylating agent that cross-links DNA strands. Docetaxel stabilizes microtubules to prevent mitotic spindle formation. Capecitabine is a fluoropyrimidine that inhibits thymidylate synthase and gets incorporated into DNA/RNA. Together, these agents provide synergistic cytotoxic effects against cancer cells.","oneSentence":"This is a combination chemotherapy regimen that uses multiple agents to damage cancer cell DNA and disrupt cell division through different mechanisms.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:01:50.810Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Breast cancer (likely indication based on typical use of this combination)"}]},"trialDetails":[{"nctId":"NCT06291064","phase":"PHASE2","title":"Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-03-18","conditions":"Triple Negative Breast Cancer","enrollment":85},{"nctId":"NCT01354522","phase":"PHASE3","title":"TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2011-05","conditions":"Breast Cancer","enrollment":204},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":"Metastatic Breast Cancer","enrollment":1460},{"nctId":"NCT00665457","phase":"PHASE2","title":"Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2004-04-15","conditions":"Breast Cancer","enrollment":3},{"nctId":"NCT00129935","phase":"PHASE3","title":"EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2004-02","conditions":"Breast Cancer","enrollment":1384},{"nctId":"NCT02897050","phase":"PHASE2","title":"Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer","status":"SUSPENDED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2016-09","conditions":"Breast Cancer","enrollment":170},{"nctId":"NCT05131893","phase":"","title":"Neoadjuvant Treatment of Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Oncology, Hungary","startDate":"2022-03","conditions":"Breast Cancer","enrollment":300},{"nctId":"NCT00365417","phase":"PHASE2","title":"Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2006-08","conditions":"Breast Cancer","enrollment":45},{"nctId":"NCT01869192","phase":"PHASE2","title":"Phase II Trial for Large ER-Negative Breast Cancers","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2003-03-05","conditions":"Malignant Neoplasm of Female Breast","enrollment":72},{"nctId":"NCT00408408","phase":"PHASE3","title":"Chemotherapy With or Without Bevacizumab in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer That Can Be Removed By Surgery","status":"UNKNOWN","sponsor":"NSABP Foundation Inc","startDate":"2006-11","conditions":"Breast Cancer","enrollment":1206},{"nctId":"NCT03085368","phase":"PHASE2, PHASE3","title":"A Randomized Controlled Trial of HER-2 Positive Breast Cancer Patients Treated With Lapatinib vs Herceptin","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2017-03-01","conditions":"HER2-positive Breast Cancer","enrollment":482},{"nctId":"NCT02846428","phase":"PHASE2","title":"To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-03","conditions":"Breast Cancer","enrollment":182},{"nctId":"NCT02115152","phase":"PHASE2","title":"Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer","status":"UNKNOWN","sponsor":"Guangxi Medical University","startDate":"2014-06","conditions":"Stage II Breast Cancer, Stage III Breast Cancer","enrollment":100},{"nctId":"NCT00262067","phase":"PHASE3","title":"A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)","status":"UNKNOWN","sponsor":"Genentech, Inc.","startDate":"2005-12","conditions":"Metastatic Breast Cancer","enrollment":1237},{"nctId":"NCT00288002","phase":"PHASE3","title":"Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer","status":"COMPLETED","sponsor":"GBG Forschungs GmbH","startDate":"2005-01","conditions":"Breast Cancer","enrollment":1500},{"nctId":"NCT00005908","phase":"PHASE2","title":"Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2000-06","conditions":"Breast Cancer, Breast Neoplasm","enrollment":30},{"nctId":"NCT01641406","phase":"PHASE2","title":"\"Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer\"","status":"UNKNOWN","sponsor":"Auxilio Mutuo Cancer Center","startDate":"2011-03","conditions":"Infiltrating Duct and Lobular Carcinoma In Situ, Invasive Lobular Breast Carcinoma, Inflammatory Breast Carcinoma","enrollment":60},{"nctId":"NCT00352378","phase":"PHASE3","title":"Primary Chemotherapy With Adriamycin/Cyclophosphamide(AC) vs Taxotere/Xeloda(TX) for Stage II and III Breast Cancer","status":"COMPLETED","sponsor":"National Cancer Center, Korea","startDate":"2002-06","conditions":"Breast Cancer","enrollment":209}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Taxotere","Xeloda","Cytoxan","doxorubicin"],"phase":"phase_3","status":"active","brandName":"Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine","genericName":"Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine","companyName":"National Cancer Center, Korea","companyId":"national-cancer-center-korea","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination chemotherapy regimen that uses multiple agents to damage cancer cell DNA and disrupt cell division through different mechanisms. Used for Breast cancer (likely indication based on typical use of this combination).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}